Codexis, Inc.
Human alpha-galactosidase variants
Last updated:
Abstract:
The present invention provides engineered human alpha-galactosidase polypeptides and compositions thereof. The engineered human alpha-galactosidase polypeptides have been optimized to provide improved thermostability, serum stability, improved cellular uptake, stability under both acidic (pH<4) and basic (pH>7) conditions, reduced immunogenicity, and improved globotriaosylceramide removal from cells. The invention also relates to the use of the compositions comprising the engineered human alpha-galactosidase polypeptides for therapeutic purposes.
Status:
Grant
Type:
Utility
Filling date:
19 Dec 2019
Issue date:
30 Aug 2022